Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Supernus Pharmaceuticals is celebrating the five-year anniversary of the FDA approval of Qelbree, its non-stimulant treatment for ADHD in patients aged six and older. Since its launch, approximately 3 million prescriptions have been filled, with over 1 million prescriptions filled in 2025 alone, indicating sustained commercial adoption.
Key figures
- Drug Name
- Qelbree (viloxazine extended-release capsules)
- Prescriptions 2025
- over 1 million
- Years since approval
- 5
- Total prescriptions since launch
- approximately 3 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.